2020
DOI: 10.1007/s11523-020-00732-y
|View full text |Cite|
|
Sign up to set email alerts
|

Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis

Abstract: Background Angiogenesis has been recognized as the most important factor for tumor invasion, proliferation, and progression in metastatic renal cell carcinoma (mRCC). However, few clinical data are available regarding the efficacy of cabozantinib following immunotherapy. Objective To describe the outcome of cabozantinib in patients previously treated with immunotherapy. Patients and methods Patients with mRCC who received cabozantinib immediately after nivolumab were included. The primary endpoint was to asses… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
26
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
9
1

Relationship

3
7

Authors

Journals

citations
Cited by 33 publications
(27 citation statements)
references
References 17 publications
1
26
0
Order By: Relevance
“…Iacovelli et al. ( 16 ) only reported the correlation between the outcomes of I-O treatment and efficacy of subsequent therapy. Furthermore, certain reports are available regarding the efficacy of specific TT after I-O regimens ( 10 , 13 , 15 , 16 , 18–20 ).…”
Section: Introductionmentioning
confidence: 99%
“…Iacovelli et al. ( 16 ) only reported the correlation between the outcomes of I-O treatment and efficacy of subsequent therapy. Furthermore, certain reports are available regarding the efficacy of specific TT after I-O regimens ( 10 , 13 , 15 , 16 , 18–20 ).…”
Section: Introductionmentioning
confidence: 99%
“…Most studies reporting individual results for second-line or subsequent VEGFR TKIs have also reported better results than those achieved in our study ( Table 3 ). 12 , 13 , 14 , 15 , 16 , 24 , 25 , 26 Rini et al., 13 in a phase III, randomized, open-label trial, reported similar results with third-line tivozanib (an ORR of 18% and a PFS of 5.6 months) and poorer results with third-line sorafenib (an ORR of 8% and a PFS of 3.9 months). On the other hand, in a prospective phase II study with axitinib in 40 patients who had received an ICI (mostly nivolumab monotherapy and less frequently the combination of ipilimumab–nivolumab), 18 (45%) achieved an OR—17 of them had partial responses—and a median PFS of 8.8 months 12 ; in a post hoc analysis, the authors did not find an association between previous type of ICI-based therapy and response to axitinib, nor with previous nivolumab monotherapy versus ipilimumab plus nivolumab.…”
Section: Discussionmentioning
confidence: 91%
“…Cabozantinib showed efficacy and activity in 84 patients previously receiving immune checkpoint inhibitors irrespective of the type and duration of previous treatments, with a median OS of 17.3 months and a median PFS of 11.5 months (95% CI, 8.3-14.7). 13 Moreover, cabozantinib showed good safety and activity in an unselected population (96 patients) treated according to real-world data from an Italian Managed Access Program. 14 Cabozantinib was administered as second-line therapy in 28 patients (29%) and as third-line therapy in 18 patients (19%), while the remaining 50 patients (52%) received cabozantinib in further treatment lines.…”
Section: Discussionmentioning
confidence: 98%